Evercore ISI Group Maintains Outperform on Caris Life Sciences, Lowers Price Target to $30

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and lowers the price target from $34 to $30.